Abstract

AbstractCamptothecin (CPT) is impeded by low solubility, non‐tumor‐targeting ability, and fast blood clearance. Self‐assembly of hydrophobic drugs into nanostructures, especially nanoparticles (NPs), can improve their anti‐cancer effects. In this study, arginine‐glycine‐aspartic acid (RGD), a hydrophilic and tumor‐targeting peptide, is conjugated with CPT through a glutathione‐cleavable disulfide bond. The synthesized amphiphilic molecule CPT‐ss‐RGD self‐assembled into stable NPs in an aqueous solution with diameters of ≈86nm. They exhibited low critical aggregation concentrations, good stability, and glutathione responsiveness. They can be specifically taken up by CRC cells through RGD integrin‐mediated uptake, and exhibit high toxicity to CRC cells and multicellular tumor spheroids. As expected, CPT‐ss‐RGD NPs prolonged the blood circulation time and enhanced the tumor accumulation of CPT, exhibiting excellent anti‐tumor growth ability and few side effects. Thus, CPT‐ss‐RGD NPs have great clinical translational potential for CRC therapy. The successful self‐assembly of the CPT‐ss‐RGD NPs provides a new method for the self‐delivery of hydrophobic therapeutics in vivo.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.